To model the cost-effectiveness (CE) of granulocyte colony-stimulating factor (G-CSF) in early-stage breast cancer when its use is directed to those most in need of the medication.
University of Pennsylvania Cancer Center and the Leonard Davis Institute of Health Economics, Department of Pediatrics, School of Medicine, Philadelphia, USA. silberj@wharton.upenn.edu
